Vaxart Inc (NASDAQ:VXRT) — Market Cap & Net Worth
Market Cap & Net Worth: Vaxart Inc (VXRT)
Vaxart Inc (NASDAQ:VXRT) has a market capitalization of $135.87 Million ($135.87 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18016 globally and #4015 in its home market, demonstrating a 4.07% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vaxart Inc's stock price $0.77 by its total outstanding shares 240059770 (240.06 Million). Analyse Vaxart Inc (VXRT) cash flow conversion to see how efficiently the company converts income to cash.
Vaxart Inc Market Cap History: 2015 to 2026
Vaxart Inc's market capitalization history from 2015 to 2026. Data shows change from $5.12 Billion to $184.85 Million (-27.42% CAGR).
Index Memberships
Vaxart Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #501 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1757 of 3165 |
Weight: Vaxart Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vaxart Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vaxart Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.54x
Vaxart Inc's market cap is 5.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.12 Billion | $24.60 Million | -$19.10 Million | 208.25x | N/A |
| 2016 | $3.25 Billion | $9.30 Million | -$25.40 Million | 349.25x | N/A |
| 2017 | $1.50 Billion | $5.84 Million | -$12.46 Million | 256.11x | N/A |
| 2018 | $451.31 Million | $4.16 Million | -$18.01 Million | 108.51x | N/A |
| 2019 | $84.14 Million | $9.86 Million | -$18.64 Million | 8.53x | N/A |
| 2020 | $1.37 Billion | $4.05 Million | -$32.22 Million | 338.79x | N/A |
| 2021 | $1.51 Billion | $892.00K | -$70.47 Million | 1687.42x | N/A |
| 2022 | $230.67 Million | $107.00K | -$107.76 Million | 2155.83x | N/A |
| 2023 | $137.51 Million | $7.38 Million | -$82.47 Million | 18.63x | N/A |
| 2024 | $158.94 Million | $28.70 Million | -$66.95 Million | 5.54x | N/A |
Competitor Companies of VXRT by Market Capitalization
Companies near Vaxart Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Vaxart Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Vaxart Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Vaxart Inc's market cap moved from $5.12 Billion to $ 184.85 Million, with a yearly change of -27.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $184.85 Million | +123.84% |
| 2025 | $82.58 Million | -48.04% |
| 2024 | $158.94 Million | +15.59% |
| 2023 | $137.51 Million | -40.39% |
| 2022 | $230.67 Million | -84.67% |
| 2021 | $1.51 Billion | +9.81% |
| 2020 | $1.37 Billion | +1529.10% |
| 2019 | $84.14 Million | -81.36% |
| 2018 | $451.31 Million | -69.82% |
| 2017 | $1.50 Billion | -53.96% |
| 2016 | $3.25 Billion | -36.60% |
| 2015 | $5.12 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Vaxart Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $135.87 Million USD |
| MoneyControl | $135.87 Million USD |
| MarketWatch | $135.87 Million USD |
| marketcap.company | $135.87 Million USD |
| Reuters | $135.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus v… Read more